NCT02676349 - Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) | Biotech Hunter

Enrollment

130

Participants

Timeline

Start Date

October 13, 2016

Primary Completion Date

June 30, 2024

Study Completion Date

October 31, 2027

Conditions

Pancreatic Carcinoma

Interventions

DRUG

mFolfirinox

oxaliplatin folinic acid irinotecan 5FU oxaliplatin

RADIATION

Chemoradiotherapy

conformational external irradiation (50.4 Gy) + capecitabine

PROCEDURE

surgery

1 to 4 weeks after neoadjuvant treatment according to tumour response

DRUG

Adjuvant chemotherapy

Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)

Trial Locations (26)

92110

Hôpital Beaujon, Clichy

94804

Hôpital Paul Brousse, Villejuif

Unknown

Institut Bergonié, Bordeaux

Polyclinique Bordeaux Nord, Bordeaux

Chu Colmar, Colmar

Hôpital Henri Mondor (APHP), Créteil

Centre Oscar Lambret, Lille

Chru Lille, Lille

Infirmerie Protestante de Lyon, Lyon

Hôpital Européen Marseille, Marseille

Hôpital La Timone, Marseille

Institut Paoli CALMETTES, Marseille

Institut du Cancer de Montpellier, Montpellier

Chu Nantes, Nantes

Hôpital Cochin (APHP), Paris

Institut Mutualiste Montsouris, Paris

Pitié Salpêtrière (APHP), Paris

Hôpital Haut-Lévêque, Pessac

CHU Reims, Reims

Centre Eugène Marquis, Rennes

Chu Rouen, Rouen

CHP Saint Grégoire, Saint-Grégoire

Institut de Cancérologie de l'Ouest, Saint-Herblain

Chru Tours, Tours

Chru Nancy, Vandœuvre-lès-Nancy

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

All Listed Sponsors

lead

Institut de Cancérologie de Lorraine

OTHER